Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group - 28/02/23
Doi : 10.1016/S1470-2045(23)00012-8
Matthew J Ehrhardt, MD MS a, *⁎ 
, Jan M Leerink, MD b, c, *, Renée L Mulder, PhD b, Annelies Mavinkurve-Groothuis, MD b, Wouter Kok, PhD c, Anju Nohria, MD d, Paul C Nathan, ProfMD e, Remy Merkx, MD f, Esmée de Baat, MD b, Ogechukwu A Asogwa, MD b, Roderick Skinner, ProfFRCPCH g, h, Hamish Wallace, ProfMD i, j, E A M Lieke Feijen, PhD b, Maëlle de Ville de Goyet, ProfMD k, l, Maya Prasad, ProfMD m, n, Edit Bárdi, PhD o, p, Vesna Pavasovic, MD q, Helena van der Pal, MD b, Brice Fresneau, PhD s, Charlotte Demoor-Goldschmidt, MD t, u, v, Ulrike Hennewig, MD w, Julia Steinberger, ProfMD x, Chris Plummer, PhD y, Ming Hui Chen, MD z, Arco J Teske, MD aa, Nadia Haddy, PhD s, t, Elvira C van Dalen, PhD b, Louis S Constine, ProfMD ab, Eric J Chow, MD ac, ad, Gill Levitt, MD r, Melissa M Hudson, ProfMD a, Leontien C M Kremer, ProfPhD b, ae, †, Saro H Armenian, ProfDO af, †
, Jan M Leerink, MD b, c, *, Renée L Mulder, PhD b, Annelies Mavinkurve-Groothuis, MD b, Wouter Kok, PhD c, Anju Nohria, MD d, Paul C Nathan, ProfMD e, Remy Merkx, MD f, Esmée de Baat, MD b, Ogechukwu A Asogwa, MD b, Roderick Skinner, ProfFRCPCH g, h, Hamish Wallace, ProfMD i, j, E A M Lieke Feijen, PhD b, Maëlle de Ville de Goyet, ProfMD k, l, Maya Prasad, ProfMD m, n, Edit Bárdi, PhD o, p, Vesna Pavasovic, MD q, Helena van der Pal, MD b, Brice Fresneau, PhD s, Charlotte Demoor-Goldschmidt, MD t, u, v, Ulrike Hennewig, MD w, Julia Steinberger, ProfMD x, Chris Plummer, PhD y, Ming Hui Chen, MD z, Arco J Teske, MD aa, Nadia Haddy, PhD s, t, Elvira C van Dalen, PhD b, Louis S Constine, ProfMD ab, Eric J Chow, MD ac, ad, Gill Levitt, MD r, Melissa M Hudson, ProfMD a, Leontien C M Kremer, ProfPhD b, ae, †, Saro H Armenian, ProfDO af, † a Department of Oncology and Department of Epidemiology and Cancer Control, St Jude Children’s Research Hospital, Memphis, TN, USA
b Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
c Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
d Department of Internal Medicine, Division of Cardiology, Brigham and Women’s Hospital, Boston, MA, USA
e Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
f Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands
g Department of Paediatric and Adolescent Haematology and Oncology, Great North Children’s Hospital, Newcastle upon Tyne, UK
h Newcastle University Centre for Cancer, Newcastle upon Tyne, UK
i Department of haematology and oncology, Royal Hospital for Sick Children and Young People, Edinburgh, UK
j University of Edinburgh, Edinburgh, UK
k Pediatric Hematology & Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
l Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium
m Division of Paediatric Oncology, Tata Memorial Hospital, Mumbai, India
n Homi Bhabha National Institute, Mumbai, India
o Hematoonokological and Immunological Outpatient Department, St Anna Children’s Hospital, Vienna, Austria
p Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria
q Department Paediatric Haemato-Oncology, Great Ormond Street Hospital for Children NHS Trust, London, UK
r Department of Oncology, Great Ormond Street Hospital for Children NHS Trust, London, UK
s Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
t Radiation Epidemiology Team, INSERM U1018, Paris-Sud XI University, Centre for Research in Epidemiology and Population Health, Cancer & Radiations Group, Gustave Roussy, Villejuif, France
u Department of Pediatric Hematology and Oncology, CHU Angers, Angers, France
v Department of Radiotherapy and Supportive care department, François Baclesse Center, Caen, France
w Department of Pediatric Hematology and Oncology, University Hospital of Giessen and Marburg, Giessen, Germany
x Department of Pediatric Cardiology, University of Minnesota School of Medicine, Minneapolis, MN, USA
y Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
z Department of Cardiology and Pediatrics, Boston Children’s Hospital, Dana-Farber Cancer Institute, Boston, MA, USA
aa Department of Cardiology, Division of Heart and Lung, University Medical Center Utrecht, Utrecht, Netherlands
ab Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
ac Department of Pediatrics, Seattle Children’s Hospital, University of Washington, Seattle, WA, USA
ad Division of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
ae Emma Children’s Hospital, Amsterdam UMC, Amsterdam, Netherlands
af Department of Pediatrics and Department of Population Sciences, City of Hope National Medical Center, Duarte, CA, USA
*Correspondence to: Matthew J Ehrhardt, Department of Oncology and Department of Epidemiology and Cancer Control, St Jude Children’s Research Hospital, Memphis, TN 38105, USADepartment of Oncology and Department of Epidemiology and Cancer ControlSt Jude Children’s Research HospitalMemphisTN38105USA
Summary |
Survivors of childhood, adolescent, and young adult cancer, previously treated with anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was exposed, are at increased risk of cardiomyopathy. Symptomatic cardiomyopathy is typically preceded by a series of gradually progressive, asymptomatic changes in structure and function of the heart that can be ameliorated with treatment, prompting specialist organisations to endorse guidelines on cardiac surveillance in at-risk survivors of cancer. In 2015, the International Late Effects of Childhood Cancer Guideline Harmonization Group compiled these guidelines into a uniform set of recommendations applicable to a broad spectrum of clinical environments with varying resource availabilities. Since then, additional studies have provided insight into dose thresholds associated with a risk of asymptomatic and symptomatic cardiomyopathy, have characterised risk over time, and have established the cost-effectiveness of different surveillance strategies. This systematic Review and guideline provides updated recommendations based on the evidence published up to September, 2020.
Le texte complet de cet article est disponible en PDF.Plan
© 2023
Elsevier Ltd. Tous droits réservés.
Vol 24 - N° 3
P. e108-e120 - mars 2023 Retour au numéro
Article précédent
- Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
- Thomas Walter, Astrid Lievre, Romain Coriat, David Malka, Farid Elhajbi, Fréderic Di Fiore, Olivia Hentic, Denis Smith, Vincent Hautefeuille, Guillaume Roquin, Marine Perrier, Laetitia Dahan, Victoire Granger, Iradj Sobhani, Laurent Mineur, Patricia Niccoli, Eric Assenat, Jean-Yves Scoazec, Karine Le Malicot, Côme Lepage, Catherine Lombard-Bohas
- Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
- Stephanie G C Kroeze, Matea Pavic, Karin Stellamans, Yolande Lievens, Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, Jasna But-Hadzic, Joachim Widder, Xavier Geets, Samuel Bral, Maarten Lambrecht, Charlotte Billiet, Igor Sirak, Sara Ramella, Ivaldi Giovanni Battista, Sergi Benavente, Almudena Zapatero, Fabiola Romero, Thomas Zilli, Kaouthar Khanfir, Hossein Hemmatazad, Berardino de Bari, Desiree N Klass, Shaukat Adnan, Heike Peulen, Juan Salinas Ramos, Michiel Strijbos, Sanjay Popat, Piet Ost, Matthias Guckenberger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?